To solidify its position in the global weight loss drug market, Danish pharmaceutical giant Novo Nordisk (NVO) is accelerating its production capacity expansion. According to local media reports on Monday, the company will invest €432 million (approximately $507 million) to upgrade its facility in Athlone, Ireland, to produce its blockbuster weight loss drug, Wegovy, for markets outside the United States. A company spokesperson has confirmed the scale of this investment. This upgrade will significantly enhance its manufacturing capabilities for current and future obesity and diabetes medications, ensuring a stable supply of key products.
This move comes at a time when Novo Nordisk is facing a cold front in the capital markets. Over the past 12 months, the healthcare company’s stock price has fallen by about 60%. Unoptimistic performance guidance, coupled with widespread investor concerns about whether the company can maintain its advantage in the long-term competition with its main rival, Eli Lilly (LLY), collectively shape the current market sentiment. Although Novo Nordisk has an approved GLP-1 weight loss drug on the market, the market generally fears that its first-mover advantage will be difficult to sustain with the introduction of similar products from Eli Lilly.
In fact, Eli Lilly is also establishing production capacity in Ireland, announcing in 2024 an $800 million investment to expand its facility in Cork, primarily to produce the active ingredients for weight loss drugs, demonstrating a full-scale rivalry between the two giants in terms of capacity and market. About two years ago, Novo Nordisk abandoned plans to build a plant near Dublin and laid off employees at the Athlone facility last September. This significant new investment can also be seen as a strategic adjustment and escalation.
The challenges Novo Nordisk faces are concrete and severe. The company expects full-year adjusted sales to decline by 5% to 13% this year, with a similar drop in operating profit. This worrying performance outlook directly led to the recent sell-off in its stock. Besides competition from legitimate manufacturers like Eli Lilly, sales are also being diverted by popular compounded versions of the drug produced by some pharmacies. Last month, Novo Nordisk filed a lawsuit against Hims & Hers Health, alleging the sale of unauthorized drugs infringing on its patents. Successfully curbing these compounded drugs, which are typically only permitted during drug shortages, would undoubtedly provide a boost to the company’s growth this year.
Despite the bleak short-term outlook, Novo Nordisk’s fundamentals remain solid in the long run. Investing in stocks is essentially a bet on a company’s long-term value, and over-focusing on short-term fluctuations can be costly. Currently, Novo Nordisk may face severe challenges, but its position as a core player in the GLP-1 drug market remains unshaken. Even if competitors’ products prove superior in some aspects, it is estimated that the global GLP-1 drug market will exceed $150 billion by 2035. The immense market space is sufficient to accommodate multiple successful companies. With its first-mover advantage and continued investment, Novo Nordisk is still capable of capturing a significant market share in the future.
